Roivant Sciences Ltd.
ROIV | NASDAQ
$38.94
-$0.83 (-2.09%)
Sep 21, 2026, 12:35 PM ET · Market open
Company Profile
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Key Executives
| Name | Position |
|---|---|
| Eric Venker | President & Chief Executive Officer of Immunovant |
| Matthew Gline | Chief Executive Officer & Director |
| Huafeng Xu | Chief Technology Officer |
| Ian Rosenblum | Chief Information Officer |
| Richard Pulik | Chief Financial Officer |
| Alex Gasner | Executive Vice President of Roivant Health |
| Deya Corzo | Chief Medical Officer-In-Residence |
| Frank Torti | President & Vant Chair |
| Jennifer Humes | Chief Accounting Officer |
| Josh Chen | General Counsel |
| Kelly Graff | Head of People |
| Mayukh Sukhatme | President, Chief Investment Officer & Director |
| Sam Kaplan | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 4 | Filing |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 27, 2026 | 8-K | Current Report |
| Aug 24, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
Roivant Sciences Ltd.
| Country | United Kingdom |
| IPO Date | Dec 7, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 721 |
| CEO | Matthew Gline |
Stock Details
| Ticker Symbol | ROIV |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001635088 |
| CUSIP Number | G76279101 |
| ISIN Number | BMG762791017 |
| SIC Code | 2834 |
Recent News
- 1 day ago / defenseworld.netInsider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells $196,236.12 in Stock
- 8 days ago / seekingalpha.comRoivant Sciences: Diverse Exposure To Biotech Niches Through Vants
- 11 days ago / seekingalpha.comRoivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- 12 days ago / seekingalpha.comRoivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
- 13 days ago / seekingalpha.comRoivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- 13 days ago / seekingalpha.comRoivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript
- 13 days ago / benzinga.comRoivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
- 13 days ago / reuters.comRoivant's experimental lung disease drug meets goals in mid-stage study
- 13 days ago / globenewswire.comPulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
- 13 days ago / globenewswire.comRoivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
Add to Watchlist
Select watchlists to add or remove ROIV